The Chemours Company

Fundamentals5.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Positive EBITDA
  • Severe leverage
  • Ongoing losses

AI
AI Summary

6.0

Chemours' specialty Opteon and immersion‑cooling businesses offer a credible re‑rating catalyst if they sustain double‑digit growth and convert adjusted margins into GAAP profits and FCF to materially deleverage, but upside is conditional and vulnerable to high leverage/refinancing risk and PFAS litigation that could consume cash or derail the pathway.

Opteon
PFAS
Deleveraging‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Positive EBITDA
  • Severe leverage
  • Ongoing losses

CC generates positive EBITDA and operating cash flow that support near-term liquidity, but extreme leverage, ongoing net losses and high operating costs materially impair its investment case.

Leverage
CashFlow

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Near-term support
  • Failed rallies
  • Elevated volatility

Price action is flat-to-slightly bearish: last month the SMA was ~$17.75 and the $17.70 close sits just below it, with nearby support around the mid-$16s and resistance near $19.00 but elevated swings between $16.41–$19.02 showing higher short-term volatility.

Flat
Bearish
Support Level: $16.4–$17.0
Resistance Level: $19.00

Volatile swings from $16.41 to $19.02 last month indicating rapid short-term moves

Sentiment & News

7.0

Key News Insights:

  • Data-center traction
  • High-yield notes
  • Elevated leverage

Chemours shows operational traction in specialty refrigerants and data‑center cooling while issuing $700M of high-yield notes amid elevated leverage and legal scrutiny.

debt
balanced

Product wins and financing give near-term momentum, but high leverage and ongoing legal scrutiny likely limit upside and keep risk-premium on the stock